A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant Btk(C481S) mutation in B‐cell malignancies

BACKGROUND AND PURPOSE: Bruton's tyrosine kinase (BTK) plays a key role in B‐cell receptor signalling by regulating cell proliferation and survival in various B‐cell malignancies. Covalent low‐MW BTK kinase inhibitors have shown impressive clinical efficacy in B‐cell malignancies. However, the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Pharmacol
Main Authors: Gui, Fu, Jiang, Jie, He, Zhixiang, Li, Li, Li, Yunzhan, Deng, Zhou, Lu, Yue, Wu, Xinrui, Chen, Guyue, Su, Jingyi, Song, Siyang, Zhang, Yue‐Ming, Yun, Cai‐Hong, Huang, Xin, Weisberg, Ellen, Zhang, Jianming, Deng, Xianming
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6932946/
https://ncbi.nlm.nih.gov/pubmed/31364164
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14809
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados